Article by Pharmacy Times

“Officials with the FDA have approved tenapanor (Ibsrela, Ardelyx), a 50 mg, twice-daily oral medication for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, according to a press release.

Tenapanor, a novel treatment, is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3. Through this mechanism, treatment results in increased bowel movements and decreased abdominal pain for patients, according to Ardelyx. IBS-C, a subtype of IBS, can cause abdominal discomfort and bloating associated with constipation in patients and symptoms can be disruptive to daily life.

“Ibsrela has the potential to provide IBS-C patients and their doctors with a novel mechanism and an innovative approach to managing IBS-C, a highly burdensome and difficult-to-treat condition affecting more than 11 million people in the United States,” Mike Raab, president and chief executive officer of Ardelyx, said in a statement.”

Click here to continue reading this article.

Enjoy our blog post? Subscribe!

Subscribe to our newsletter and receive the latest news from our team. Learn more about the people behind the prescription, latest events, newest client programs, industry resources, and much more.

Thank you! Please check your email to confirm your subscription and watch for info from us soon!